Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | Filing |
| 2022-01-21 4:01 pm Sale | 13G | CHINOOK THERAPEUTICS INC. KDNY | ATP Life Science Ventures L.P. | 0 0.000% | -4,028,937 (Position Closed) | View |
| 2021-06-28 8:56 pm Sale | 13D | Akero Therapeutics Inc. AKRO | ATP Life Science Ventures L.P. | 674,640 1.900% | -5,164,229 (-88.45%) | View |
| 2021-06-28 8:54 pm Sale | 13D | Stoke Therapeutics Inc. STOK | ATP Life Science Ventures L.P. | 1,912,256 5.200% | -15,293,789 (-88.89%) | View |
| 2020-11-27 4:58 pm Purchase | 13D | Stoke Therapeutics Inc. STOK | ATP Life Science Ventures L.P. | 17,206,045 47.500% | 419,332 (+2.50%) | View |
| 2020-11-16 4:14 pm Purchase | 13G | CHINOOK THERAPEUTICS INC. KDNY | ATP Life Science Ventures L.P. | 4,028,937 9.600% | 4,028,937 (New Position) | View |
| 2020-07-14 5:06 pm Purchase | 13D | Akero Therapeutics Inc. AKRO | ATP Life Science Ventures L.P. | 5,838,869 17.200% | 423,666 (+7.82%) | View |